REPEAT/Media Advisory/OHC - Day of Action at Ontario Legislature to Stop Hospital Closures
Article content
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — On Wednesday May 14, people from across Ontario will be heading into the Ontario Legislature for a 'Day of Action' to ask the Ford government to stop closing their local hospitals and to provide the resources needed for the overcrowded remaining hospitals. People will be coming in from towns where emergency departments, urgent care centres, inpatient beds and other critical services are being closed down. Others are coming in from communities where their hospital is running at more than 100% capacity without resources to provide for patients. Delegations will be coming from Thessalon, Blind River, Port Colborne, Chesley, Fort Erie, Welland, St. Catharines, town of Durham, Durham region, Hamilton, Lindsay, Toronto, Minden and other communities. More than 140 people will be coming. The group will watch the Legislative session from the galleries, hold a press conference, and have meetings with politicians and their staff, and finish the day with a visible rally at the top of 'hospital row.'
Article content
Article content
Article content
What: Vitally important hospital services are continuing to close and entire local hospitals that have lasted for almost a hundred years, built by their local communities, are under threat. In Ontario, emergency departments and urgent care centres now routinely close overnight, on weekends, and even permanently. Some close without warning to their communities. The inpatient beds in Thessalon and the town of Durham have closed. Fort Erie and Port Colborne urgent care services have perma n ently closed overnight and other hospital services in the Nia g ara region are under threat. The situation has not improved. In 2024, there were record breaking numbers of closures: 1,117 emergency department closures, 1,001 urgent care centre closures, three obstetrics unit closures, one ambulance base closure, one inpatient bed closure, and one labour and delivery unit closure. That is worse than even 2023 and 2022. Prior to 2021 emergency department closures were so rare as to be unheard of.
Article content
Article content
At the same time, the Ford government has set no standard requiring services to remain open. The province funds public hospitals at the lowest rate per p e rson out of all the provinces and territories while shunting more than 200% funding increases to private for-profit clinics. Small, rural and northern hospitals are dependent on locum funding that is short term and has often been belatedly announced at the last minute. There continues to be no plan to fix the hospital crisis.
Article content

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Ottawa Citizen
14-05-2025
- Ottawa Citizen
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Article content Article content SAN DIEGO and TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) has been selected for oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy. Article content The TUS+VEN+AZA triplet is being developed as the only safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. As reported prior, the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet, have demonstrated safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. The oral presentation at EHA will include updated safety, complete remission, minimal residual disease (MRD) clinical findings, and longer duration of follow-up. Article content Details of the presentation are as follows: Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Session: Oral Presentations: Acute Myeloid Leukemia – Clinical Session Date and Time: Thursday, June 12, 2025, 5:00 – 6:15 pm CEST Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine Abstract #: S139 Article content Article content The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. Article content The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available.

Ottawa Citizen
14-05-2025
- Ottawa Citizen
Hydreight Technologies to Present at Maxim Group's 2025 Virtual Tech Conference & the CEM Bermuda Capital Event
Article content VANCOUVER, British Columbia and LAS VEGAS, May 14, 2025 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. ('Hydreight' or the 'Company') (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform transforming mobile and telehealth services across the United States, today announced that Shane Madden, CEO of Hydreight, will be presenting at the following investor conferences in June 2025: Article content Article content Article content Hosted by: Maxim Group LLC Date: June 3–5, 2025 Presentation Time: Tuesday, June 3rd at 12:30 PM PT / 3:30 PM ET Location: Virtual (M-Vest Platform) Registration: Click here to attend Article content Maxim's 2025 Virtual Tech Conference explores how emerging growth companies are leveraging technologies such as AI and telehealth to shape the future of healthcare and other industries. Hydreight's presentation will highlight its national healthcare infrastructure, proprietary technology platform, and strategy to scale its direct-to-consumer and pharmacy verticals. Article content CEM Bermuda Capital Event Article content Hydreight will participate in one-on-one meetings with institutional and high-net-worth investors throughout the conference. Article content Hydreight recently reported audited financial results for the fiscal year ended December 31, 2024, achieving several financial and operational milestones: Article content Article content Please see SEDAR+ for the Company's audited annual consolidated financial statements and MD&A for the year ends. Article content In 2024, Hydreight expanded its offerings to include Liraglutide, NAD+, TRT, peptide therapies, and oral weight-loss medications. The Company also secured strategic partnerships with national health franchises and clinical experts, including The DRIPBaR and Dr. Franklin Joseph.

Ottawa Citizen
14-05-2025
- Ottawa Citizen
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
Article content KetaVault™ to Provide Partners Unprecedented Access to PharmaTher's Extensive Regulatory, Manufacturing, and Clinical Ketamine Data, Aiming to Expedite New Therapies and Market Entry Article content Article content TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the 'Company' or 'PharmaTher') (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the research and commercialization of ketamine for unmet medical needs, today announced the launch of KetaVault™. This innovative, world-first portal offers pharmaceutical and biotech companies, academic and clinical researchers, and government agencies to partner with PharmaTher for direct access to its comprehensive proprietary data on ketamine. KetaVault™ is strategically designed to streamline and accelerate clinical trials, regulatory submissions, and commercialization initiatives for ketamine-based therapies. Article content Article content The launch of KetaVault™ is strategically timed with the Company's anticipated FDA approval for its ketamine product, which has an approval goal date of June 4, 2025. This dual milestone underscores PharmaTher's commitment to leading innovation in the ketamine space. KetaVault™ is positioned to be a pivotal catalyst, empowering partners to leverage PharmaTher's deep expertise and data to unlock new therapeutic avenues for ketamine in areas of high unmet medical need and for emergency use applications, potentially revolutionizing treatment paradigms. Article content Fabio Chianelli, Chairman and CEO of PharmaTher, commented: 'PharmaTher is committed to revolutionizing patient care through ketamine. With KetaVault™, PharmaTher isn't just sharing data; we're igniting a new era of collaborative ketamine innovation. This platform is a bold step toward unlocking the full potential of ketamine, empowering our partners with unprecedented access to our years of dedicated work, rich proprietary insights, and collectively accelerating the journey towards novel treatments for patients in critical need. As we near our FDA approval goal date for ketamine, KetaVault™ will serve as a critical tool to expand ketamine's therapeutic reach and solidify PharmaTher's leadership in the market for ketamine, creating significant value for our partners and shareholders.' Article content Article content Expedited Regulatory Pathways: Leverage existing data to potentially streamline investigational new drug applications and emergency use authorizations. De-risked Clinical Development: Inform trial design, safety and efficacy data, and identify promising indications based on robust existing research. Enhanced Commercial Strategy: Gain insights into manufacturing, control, and product development for market readiness. Article content Regulatory Filings: Investigational New Drug (IND) Applications. Comprehensive Drug Information: Investigator's Brochures. Manufacturing Insights: Chemistry, Manufacturing, and Control (CMC) data. Clinical Research & Data: In-depth clinical study protocols and research data for indications including Parkinson's disease. Orphan Drug Designations: Access to information supporting FDA Orphan Drug Approvals for Amyotrophic Lateral Sclerosis, Rett Syndrome, Complex Regional Pain Syndrome, Status Epilepticus, and ischemia/reperfusion injury during solid organ transplantation. Novel Delivery Systems: Product development programs and regulatory filings for PharmaTher's ketamine microneedle patch and subcutaneous wearable pump.